New York, Feb 12, 2026, 08:33 EST — Premarket.
- Hinge Health added 0.4% ahead of the bell, building on its 17.3% jump from the prior session.
- Digital MSK care provider expects 2026 revenue to land between $732 million and $742 million, after turning in a strong fourth quarter.
- RBC kept its Outperform rating in place, but trimmed the price target, pointing to improved margins and where the stock trades on valuation.
Hinge Health tacked on 0.4% to $38.90 before the bell Thursday, building on Wednesday’s 17.3% leap that pushed shares to $38.76 by the close. The move came after the company laid out its 2026 outlook.
It’s a notable turn. Investors are backing health tech IPOs again, but only when growth comes packaged with discipline. Hinge Health checks both boxes: faster revenue, better margins, plus a buyback to cut shares outstanding.
Hinge Health hit the market in May, opening at $32 a share. That price turned heads, standing out as a marker of IPO demand after a long stretch with few companies going public.
Hinge Health turned in a 46% year-over-year revenue surge for the fourth quarter, bringing in $170.7 million. Adjusted diluted EPS landed at $0.49. CEO Daniel Perez described the stretch as “an exceptional quarter,” crediting better win rates and more eligible lives as the year wrapped. ir.hingehealth.com
The company expects revenue to land between $732 million and $742 million in 2026. First-quarter guidance calls for $171 million to $173 million on the top line, with an adjusted operating margin—stripping out stock-based comp and a few other items—hovering near 18% at the midpoint.
The company submitted its latest quarterly report and related materials through an 8-K, per an SEC filing.
RBC Capital Markets dropped its price target on the stock to $50 from $60, though it left its Outperform rating unchanged. “Another solid quarter of revenue outperformance and margin expansion,” the firm said. RBC still sees “a long runway ahead” as the company moves toward a larger addressable market. Shares are trading at about three times RBC’s 2027 revenue estimate. Investing.com
Hinge Health pitches its digital platform for musculoskeletal problems—so, joint or muscle pain—directly to employers and health insurers. The company says its software, along with remote clinical staff, delivers more care and brings overall medical costs lower.
Even so, this quarter forced investors to face the numbers: Hinge Health posted a sizable GAAP operating loss for 2025, though the company highlighted its adjusted profitability. The gap between its GAAP and non-GAAP results stands out—how quickly that gap narrows could be critical for a stock that’s shown plenty of swings since its IPO.
Management says the annual Form 10-K should arrive “in the coming weeks.” Investors have their eyes on that, with the next earnings update due May 7. The Motley Fool
